Purdue Pharma has completed the initial phase of a study investigating the use of nalmefene hydrochloride injection (HCl) in emergency department (ED) environments. Researchers are currently analyzing data, with results anticipated later this year.
Nalmefene HCl injection is an opioid antagonist used to reverse opioid drug effects and manage suspected or known overdoses. The study aims to provide comprehensive data on its administration, including its effectiveness in ED settings.
The Clinical Outcomes from Injectable Nalmefene in the Emergency Department (COINED) study evaluates the success rate of nalmefene in reversing acute opioid toxicity compared to naloxone, as well as the dosages required. It also examines the clinical course of patients after receiving an opioid antagonist, considering factors such as length of ED stay and additional medications used.
The study’s purpose is to enhance understanding of long-acting reversal agents’ impact on patients in the evolving opioid environment. Results may inform healthcare providers’ treatment decisions for patients experiencing opioid toxicity.
The COINED study is an observational retrospective cohort study involving data analysis from electronic health records and medical charts of approximately 120 patients who received either nalmefene or naloxone in ED settings. The study was conducted at two medical centers and utilized the clinical judgments of healthcare providers in selecting the type of opioid antagonist administered.
Healthcare professionals can access additional information about nalmefene at www.nalmefenehcl.com.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
